The team of scientists – including first author Jose Moreno, M.D., clinical associate professor of urology at Jefferson Medical College of Thomas Jefferson University in Philadelphia and the Kimmel Cancer Center at Jefferson – looked at circulating tumor cells (CTCs) in 240 men with metastatic prostate cancer that failed hormone-depletion therapy. They compared levels prior to chemotherapy and after two to five weeks of treatment. They found that those men with more than five tumor cells per blood sample had a worse prognosis than those who had fewer cells. One half of the patients with more than five CTCs lived at least 10 months, whereas half of the men with fewer tumor cells lived substantially longer – 21 months.
Dr. Moreno presents the trial’s findings June 4, 2007 at the annual meeting of the American Society of Clinical Oncology in Chicago.
The results of the 65-site trial also showed that those patients who underwent chemotherapy and whose CTC number went down fared better and had a more favorable prognosis. That is, the level of response to chemotherapy was reflected in the CTC level, notes Dr. Moreno. The numbers held up even after up to 20 weeks of treatment. “If chemotherapy doesn’t reduce the CTC level, it’s information that enables the physician to change the drug regimen or perhaps stop treatment,” he says.
Dr. Moreno notes that the prostate specific antigen has been a powerful biomarker for cancer presence and a useful way to gauge treatment effectiveness for years, though it has some flaws. He thinks that the group’s findings show that CTCs can be a stronger marker.
“The other exciting aspect is in looking at men with earlier stage prostate cancer,” he says. “One in four men may have circulating tumor cells at an early stage of prostate cancer. If we can identify those patients, perhaps we can observe and not treat with radical surgery because their cancer is more dormant.”
Huntington Valley, Pa.-based Immunicon Corporation’s technology enabled researchers to visualize circulating tumor cells by using immunomagnetic beams that bind to the cell surface. It’s been Food and Drug Administration-approved for clinical use in breast cancer.
Immunicon currently is working with several pharmaceutical companies in identifying targets on circulating tumor cells that are susceptible to various chemotherapy drugs, he explains. “Then doctors can select specific chemotherapy agents for specific patients,” Dr. Moreno says. “The first immediate application is personalized medicine in advanced metastatic prostate cancer.”
In addition, certain tests can be performed on CTCs, he notes. One future goal is to better characterize the tumor cells virulence.
Yet, one limitation is that “we didn’t find as many circulating cells as we thought we would.” In the study, circulating tumor cells weren’t found in 38 percent of the men. “That might mean a better prognosis, but in fact their prognosis still isn’t very good,” he points out. “There are some limitations in our ability to detect them.”
Steve Benowitz | EurekAlert!
Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine
University of Maryland researchers contribute to historic detection of gravitational waves and light created by event
On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...
Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.
Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....
Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).
When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...
Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.
How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...
Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.
It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...
17.10.2017 | Event News
10.10.2017 | Event News
10.10.2017 | Event News
20.10.2017 | Information Technology
20.10.2017 | Materials Sciences
20.10.2017 | Interdisciplinary Research